• Sharanjit Kaur MM university
  • Harinder Jot Singh MM university
  • Sanjay Nayyar
  • Navpreet Kaur MM university
  • Sami Manzoor MM University


Objectives: Metabolic agents such as trimetazidine offer a benefits role of cytoprotection in ischemic heart disease (IHD) through an inhibition of
cardiac fatty acid oxidation and improving myocardial glucose utilization. To show the efficacy of trimetazidine in reducing the incidence of angina
and improving exercise tolerance.
Methods: 50 diagnosed cases of chronic stable angina taking conventional treatment were subjected to stress test (treadmill) on day 0 to evaluate
the parameters such as effort duration and ST-segment changes at the end of the exercise. After evaluation, the patients will be given trimetazidine
for a period of 6-week at a dosage of 60 mg (in three divided doses) daily. After completion of the stipulated period, a second stress test evaluation
was done.
Results: The present study consisted of 50 patients of chronic stable angina, out of which 35 were males and 15 were female patients. It was seen that
trimetazidine intake brought about an increase in the mean exercise time from 7.086±0.96 to 8.3±0.75 and showed good symptomatic improvement
(in 31 patients). 15 patients did not show any appreciable (>1 minute) increase in the effort duration. No severe symptoms were reported to warrant
discontinuation of the drug.
Conclusion: Trimetazidine is an effective anti-anginal as monotherapy as well as an adjuvant to conventional anti-anginals as a cytoprotective agent.
Keywords: Trimetazidine, Cytoprotective, Metabolic modulator, Ischemic heart disease.

Author Biographies

Sharanjit Kaur, MM university

Associate Professor Pharmacology Maharishi Markandeshwar medical college and hospital, Kumarhatti Solan 173211

Harinder Jot Singh, MM university

Associate Professor Physiology Maharishi Markandeshwar medical college and hospital, Kumarhatti Solan 173211

Navpreet Kaur, MM university

Professor and Head Pharmacology MMMCH Solan

Sami Manzoor, MM University

Assistant prof pharmacology MMMCH solan



Dyspnea Weakness Palpitation

and dyspnea

Presenting compliant before therapy 15 22 10 1 2

No. of patients showing improvement

after trimetazidine therapy

12 6 1 2

Table 3: ST-segment improvement and increase in exercise

time (after trimetazidine)

Sign and Symptom


Srinath Reddy K, Shah B, Varghese C, Ramadoss A. Responding to the

threat of chronic diseases in India. Lancet 2005;366(9498):1744-9.

Mohan V, Sandeep S, Deepa R, Shah B, Varghese C. Epidemiology of

type 2 diabetes: Indian scenario. Indian J Med Res 2007;125(3):217-30.

Gupta R. Trends in hypertension epidemiology in India. J Hum

Hypertens 2004;18(2):73-8.

Prabhakaran D, Chaturvedi V, Shah P, Manhapra A, Jeemon P, Shah B,

et al. Differences in the prevalence of metabolic syndrome in urban and

rural India: A problem of urbanization. Chronic Illn 2007;3(1):8-19.

Stanley WC, Marzilli M. Metabolic therapy in the treatment of

ischaemic heart disease: The pharmacology of trimetazidine. Fundam

Clin Pharmacol 2003;17(2):133-45.

Lee L, Horowitz J, Frenneaux M. Metabolic manipulation in

ischaemic heart disease, a novel approach to treatment. Eur Heart J


Increase in exercise time Improvement

in ST-segment

<1 minute >1 minute

No. of patients 16 34 33

Percentage of patients 32 68 66

Banach M. The role of trimetazidine in the treatment of heart diseases.

Poznan: Termedia Publishing House; 2006.

Chrusciel P, Rysz J, Banach M. Defining the role of trimetazidine in the

treatment of cardiovascular disorders: Some insights on its role in heart

failure and peripheral artery disease. Drugs 2014;74(9):971-80.

Asian J Pharm Clin Res, Vol 9, Issue 2, 2016, 298-301

Kaur et al.

Astarie-Dequeker C, Joulin Y, Devynck MA. Inhibitory effect of

trimetazidine on thrombin-induced aggregation and calcium entry into

human platelets. J Cardiovasc Pharmacol 1994;23(3):401-7.

Selzer A, Cohn K. On the interpretation of the exercise test. Circulation


Detry JM, Sellier P, Pennaforte S, Cokkinos D, Dargie H, Mathes P.

Trimetazidine: A new concept in the treatment of angina. Comparison

with propranolol in patients with stable angina. Trimetazidine

European Multicenter Study Group. Br J Clin Pharmacol


Sellier P, Broustet JP. Assessment of anti-ischemic and antianginal

effect at trough plasma concentration and safety of trimetazidine

MR 35 mg in patients with stable angina pectoris: A multicenter,

double-blind, placebo-controlled study. Am J Cardiovasc Drugs


Marzilli M, Klein WW. Efficacy and tolerability of trimetazidine instable

angina: A


of randomized, double-blind, controlled


Coron Artery

Dis 2003;14(2):171-9.

Szwed H, Pachocki R, Domzal-Bochenska M, Szymczak K,

Szydlowski Z, Paradowski A, et al. Efficacy and tolerance of

trimetazidine, a metabolic antianginal, in combination with a

hemodynamic antianginal in stable exertion angina. TRIMPOL I, a

multicenter study. Presse Med 2000;29(10):533-8.

Szwed H, Sadowski Z, Elikowski W, Koronkiewicz A, Mamcarz A,

Orszulak W, et al. Combination treatment in stable effort angina using

trimetazidine and metoprolol: Results of a randomized, double-blind,

multicentre study (TRIMPOL II). TRIMetazidine in POLand. Eur Heart

J 2001;22(24):2267-74.

Vitale C, Spoletini I, Malorni W, Perrone-Filardi P, Volterrani M,

Rosano GM. Efficacy of trimetazidine on functional capacity in

symptomatic patients with stable exertional angina – The VASCOangina


Int J Cardiol 2013;168(2):1078-81.

Manchanda SC, Krishnaswami S. Combination treatment

with trimetazidine and diltiazem in-stable angina pectoris.

Heart 1997;78(4):353-7.

Manchanda SC. Treatment of stable angina with low dose diltiazem

in combination with the metabolic agent trimetazidine. Int J Cardiol




How to Cite

Kaur, S., H. J. Singh, S. Nayyar, N. Kaur, and S. Manzoor. “ROLE OF TRIMETAZIDINE, A CYTOPROTECTIVE AGENT IN ISCHEMIC HEART DISEASE”. Asian Journal of Pharmaceutical and Clinical Research, vol. 9, no. 2, Mar. 2016, pp. 298-01,



Original Article(s)